Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors

Inclusion Criteria:

Phase 0 (Proof-of-Concept)

* Patients with one of the following:

  * Early-stage breast cancer having completed participation in IRB# 15-147
  * Diagnosed with the prespecified solid tumors: endometrial, breast or prostate cancer
  * Underwent a diagnostic lung biopsy within 14 days prior to enrollment
  * Age \>18 years
  * BMI ≤ 40
  * Has ≥ 20 mg of fresh normal lung and suspicious lung tissue from the standard of care diagnostic biopsy available for snap freezing and single-cell sequencing (lung patients only)
  * At least a 2-week window from study enrollment to scheduled surgical resection (patients with prespecified solid tumors only)
  * Performing less than 30 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self report If \> 30 minutes but less than 90 minutes, patients may be eligible, at the discretion of the PI.
  * Cleared for exercise participation as per screening clearance via PAR-Q+
  * Willingness to comply with all study-related procedures

Phase 1a (Dose-Finding/Escalation)

* Patients with operable untreated prostate cancer scheduled for surgery
* At least a 2-week window from study enrollment to scheduled surgical resection (patients with prespecified solid tumors only)
* Age \> 18 years
* BMI \</=40
* If BMI \>40, patients may be eligible, at the discretion of the PI
* Performing \</= 30 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self report If \> 30 minutes but less than 90 minutes, patients may be eligible, at the discretion of the PI.
* Cleared for exercise participation as per screening clearance via PAR-Q+
* Willingness to comply with all study-related procedures

Exclusion Criteria:

* Use of any selective estrogen receptor modulator or aromatase inhibitor within 6 months of study entry, including, but not limited to: tamoxifen, raloxifene, arzoxifene, acolbifene, anastrozole, exemestane, and letrozole (for preoperative breast, endometrial, and prostate patients in Phase 0 only)
* Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound the effect of exercise on study outcomes
* Men receiving GNRH agonists and antagonists as well as any antiandrogrens
* Any neoadjuvant anticancer treatment of any kind for the cancer of interest
* Any history of systemic anticancer therapy
* Any other diagnosis of invasive cancer currently requiring active treatment
* Metastatic malignancy of any kind
* Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation.